argenx SE Stock 12‑Month Price Target Cut to $1192.11, Implies 28% Upside
Analysts lowered argenx SE's average price target from $1201.23 to $1192.11, with a range of $823 to $1450. This implies a 28% upside from the Oct. 7 closing price. The consensus rating remains 'Buy' among 28 analysts, with 24 Buys, 4 Holds, and 0 Sells.
How this was made
The 30-second read
Why it matters
The reduction signals a slight shift in analyst sentiment but still indicates a sizable upside from current pricing, potentially prompting modest buying interest.
Market read
The price target adjustment provides fresh guidance for traders, highlighting a modest upside opportunity in the biotech space.
What to watch
Potential upcoming clinical trial results or regulatory news could outweigh the modest target change.
Background
Analyst consensus price target for argenx SE was revised downward, with the average now at $1192.11 versus $1201.23 previously.
Ticker impact
Analysts lowered the average 12‑month price target to $1192.11, implying a 28% upside from the Oct 7 close.
likely modest upside as analysts price in 28% potential
The new target reflects analyst view of upside despite a slight reduction, which may attract buying interest.
Market effects
Biotech sector may see similar target revisions as analysts reassess valuations.
European biotech investors could adjust positions based on the updated target.
May influence global biotech sentiment and comparable companies' price targets.
Counterpoint
Some investors may view the target cut as a warning sign and consider short positions.
Key entities
- companyargenx SE
Swiss biotech firm whose price target was revised.
- data_providerFactSet
Source of the analyst consensus data.
